Are boiled eggs good for you?
Are boiled eggs good for you?
Show Caption
Hide Caption
How to cook your eggs every way
Whether it's scrambled, over easy or poached, here's how to cook your perfect egg.
If you're after a nutrient-dense breakfast, boiled eggs are a quick and easy way to pack in a few essential nutrients –from antioxidants to B vitamins to choline.
Because you're not adding extra oils or fats into the cooking process, boiled eggs are considered to be one of the healthiest kinds of eggs to eat, says Jeremy O'Neal, a board-certified specialist in obesity and weight management, and licensed dietitian nutritionist specialist in the UI Health Bariatric Surgery Program.
All around, boiled eggs are a low calorie, protein-rich food. What else is there to know about this breakfast staple? We asked the experts to break down all the nutrients found in boiled eggs, how much protein they actually contain and why (for most people) they're a great food to incorporate into an everyday, balanced diet.
How many calories in an egg?
One large boiled egg contains 72 calories, nearly 5 grams of fat and around 1.5 grams of saturated fat, says O'Neal. Eggs, and egg yolks in particular, pack a punch with vitamins and minerals. They're a good source of vitamin A, B vitamins, riboflavin, folate, iron and zinc, he says.
Eggs are also one of the best sources of choline, a mineral that's especially important during pregnancy because it supports the production of acetylcholine, which helps with muscular contractions, he says. Choline has also shown to be important in promoting cognitive function in older adults, says Dr. Amar Dave, a lifestyle medicine specialist with MedStar Health.
How much protein is in an egg?
There's around 6 to 7 grams of protein in one large boiled egg, says O'Neal. Boiled eggs are protein-rich, though you can't rely on them alone to meet all your daily protein needs (which is essential for muscle growth and recovery).
Your protein intake depends on two factors: your body weight, and how much you exercise. For adults, the recommended dietary allowance (RDA) of protein is at least 0.8 grams of protein per kilogram of body weight, according to Harvard Health.
So, if someone weighs 180 pounds, it's recommended they eat around 65 grams of protein a day, says O'Neal. If you're someone who's very active, you're going to need to consume a bit more protein than the average person, somewhere between 1.2 grams to 2 grams of protein per kilogram of body weight. If you're pregnant, it's also recommended your protein intake be higher than average, around 1.1 grams of protein per kilogram of body weight, he says.
What are seed oils? What you need to know about the food group deemed the 'hateful eight'
How often can I eat boiled eggs?
In the context of a balanced diet, for most people, it's perfectly fine to eat two to three boiled eggs per day if you wanted to, says O'Neal.
The Dietary Guidelines for America 2020-2025 recommends eating a wide variety of fruits, vegetables, grains, dairy (or soy as an alternative), healthy oils and protein-rich foods. It's especially important to diversify your protein sources, says Dave. To help meet your protein goals, consider incorporating a mix of lean meats, poultry and eggs. As for plant-based protein sources, he recommends eating foods like steel cut oats, legumes, seeds, lentils and tofu.
Noted: Building muscle requires a higher protein intake. But eating too much protein isn't safe.
Can I eat boiled eggs if I have high cholesterol?
If you have high cholesterol, you may have heard you should either limit your intake of eggs, or avoid eating them entirely. The concern surrounding eggs and cholesterol is mainly to do with eating the egg yolk, where the majority of the dietary cholesterol is concentrated, says O'Neal. One large egg contains approximately 200 milligrams of dietary cholesterol, according to the USDA's Food Data Central.
'Eggs are definitely a larger source of dietary cholesterol, but the association between regular dietary cholesterol consumption, and then high (blood) cholesterol and coronary artery disease, has not been well proven,' says Dave. The relationship between dietary and blood cholesterol has been up for debate for decades, and according to a 2022 review published in Nutrients, recent research still hasn't been able to establish a direct link.
So, if you're someone who's at risk for high cholesterol, it's probably more important to turn your attention to the amount of saturated fat that a boiled egg contains. That's because diets high in saturated fat are strongly correlated with high blood cholesterol, which increases your risk for heart disease and stroke, says Dave. However, even if you have high cholesterol, it still doesn't mean you need to avoid boiled eggs full stop. If you're following a balanced dietary pattern that limits your intake of saturated fat in other areas, like swapping red meats for lean meat, avoiding ultra-processed foods and instead eating lots of vegetables, boiled eggs could (in moderation) could be a nutritious, protein-rich addition to your diet, O'Neal says.
And as always, if you have any dietary concerns, talk to your healthcare provider to discuss an eating pattern that supports your individual health needs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Rise in VC activity tees up ‘strong year' for medtech funding: PitchBook
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Increases in venture capital investments have positioned 2025 to be a 'strong year for global medtech funding,' according to a report from market data research firm PitchBook. First quarter VC funding totaled $4.1 billion, the highest it has been since 2022. The number of confirmed transactions hit 216, reversing a four-quarter decline. However, the uptick in medtech mergers and acquisitions that PitchBook predicted under the second Trump administration has yet to emerge, and antitrust regulators are still challenging deals. Medtech VC activity fell in both 2022 and 2023, according to PitchBook. Last year brought signs that the market might be bottoming. The number of VC investments fell for the third year in a row, but the amount of funding was higher than in 2023. Signs of a VC recovery continued into the first quarter of 2025, when the $260 million investment in whole-body-imaging startup Neko Health was the largest of 11 rounds worth $100 million or more. With Elon Musk's brain implant startup Neuralink raising $650 million this month, PitchBook said preliminary data for the second quarter shows more than $3 billion of medtech VC funding so far. VC exits are rare, though. PitchBook said there were no significant medtech VC exits in the first quarter, and the total exit value remained roughly in line with the previous two quarters. Total exit value in recent years has been driven by rare big deals, such as Tempus AI's initial public offering in 2024 and the $6 billion acquisition of Athelas in 2023. PitchBook highlighted three notable exits that closed in the first quarter: Beta Bionics' IPO, Hologics' $350 million takeover of Gynesonics and Boston Scientific's $540 million acquisition of SoniVie. The level of activity has fallen short of PitchBook's expectations. 'Our earlier thesis that the new U.S. presidential administration's more lenient regulatory stance would catalyze M&A activity has yet to play out, as broader market turbulence in early 2025 has complicated dealmaking conditions across sectors,' PitchBook said. 'Additionally, regulatory resistance remains a headwind.' PitchBook cited the Federal Trade Commission's legal challenge to the $627 million private equity buyout of Surmodics as evidence of ongoing regulatory resistance. The FTC challenged the deal on the grounds it 'would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate significant head-to-head competition.' Recommended Reading Medtech venture investment recovery continues, but startup M&A remains limited: Pitchbook Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Medscape
6 hours ago
- Medscape
ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care. Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
